痛风
药物发现
医学
药品
药理学
计算生物学
药物重新定位
计算机科学
内科学
数据科学
生物信息学
生物
作者
Naoyuki Otani,Motoshi Ouchi,Hideo Kudo,Shuichi Tsuruoka,Ichiro Hisatome,Naohiko Anzai
标识
DOI:10.1080/17460441.2020.1755251
摘要
Available treatment options for hyperuricemia are limited. Allopurinol, a urate synthesis inhibitor, is generally administered at a reduced dosage to patients with renal impairment. Some URAT1 inhibitors have an unfavorable side effect profile. A promising strategy for treatment is the use of uricosuric agents that inhibit transporters (e.g. URAT1, URATv1/GLUT9, OAT10) which reabsorb urate from the urine.
科研通智能强力驱动
Strongly Powered by AbleSci AI